PDCD1 and small cell lung carcinoma: Programmed cell death‐1 (PD‐1) inhibitor monotherapy, such as nivolumab and pembrolizumab, were used as third‐line and late‐line treatment options for ED‐SCLC; however, they had no significant survival benefits.12, 13